Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment
This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | OHSU Knight Cancer Institute Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT06784167 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the immune responses to vaccines in patients with multiple myeloma and non-Hodgkin lymphoma who have undergone CAR-T therapy. It aims to determine whether CAR-T treatment affects the effectiveness of vaccines against various diseases, including measles, mumps, and rubella. The study will measure antibody titers before and after CAR-T therapy and evaluate changes in antibody levels in relation to vaccination and immune cell counts. Blood samples will be collected, and medical records will be reviewed throughout the study.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of multiple myeloma or specific types of non-Hodgkin lymphoma who are preparing for CAR-T therapy.
Not a fit: Patients currently using immunosuppressive agents or those with uncontrolled infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help optimize vaccination strategies for patients undergoing CAR-T therapy, improving their overall immune protection.
How similar studies have performed: While this approach is relatively novel, similar studies assessing vaccine responses in immunocompromised populations have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \* Willingness to provide written informed consent before any study-specific procedures or activities are performed * Age ≥ 18 years of age, at the time of consent * Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed * History of prior vaccination against common VPD * Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days * Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus Exclusion Criteria: * \* Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints * Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable
Where this trial is running
Portland, Oregon
- OHSU Knight Cancer Institute — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Amrita Desai — OHSU Knight Cancer Institute
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.